* Zymeworks Inc ZYME.OQ ZYME.O is expected to show a
fall in
quarterly revenue when it reports results on May 2 for the
period ending March 31 2024
* The Middletown Delaware-based company is expected to
report a
51.0% decrease in revenue to $17.431 million from $35.58 million
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Zymeworks Inc is for a
loss
of 29 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 0.3%
in the last three months.
* Wall Street's median 12-month price target for Zymeworks
Inc is
$14.60, above its last closing price of $8.58.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.46 -0.43 -0.20 Beat 53.9
Jan. 1 2023 -0.50 -0.47 -0.41 Beat 12.7
Jan. 1 0001 -0.49 -0.47 -0.76 Missed -61.6
Mar. 31 2023 -0.55 -0.54 -0.36 Beat 32.9
Dec. 4.44 4.84 4.65 Missed -3.9
31 2022
Sep. 30 2022 -0.91 -0.92 -0.72 Beat 21.8
Jun. 30 2022 -0.94 -0.96 -0.97 Missed -0.7
Jan. 1 0001 -1.37 -1.67 -1.03 Beat 38.2
This summary was machine generated April 30 at 23:39 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)